Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 272Carcinoma, Non-Small-Cell Lung 195Prostatic Neoplasms 171Stomach Neoplasms 100Lung Neoplasms 93Squamous Cell Carcinoma of Head and Neck 74Head and Neck Neoplasms 69Esophageal Neoplasms 56Neoplasms 47Neoplasm Metastasis 36Pancreatic Neoplasms 31Nasopharyngeal Carcinoma 30Ovarian Neoplasms 27Sarcoma 26Urinary Bladder Neoplasms 25Triple Negative Breast Neoplasms 20Adenocarcinoma 19Carcinoma, Squamous Cell 17Adenocarcinoma Of Esophagus 17Esophageal Squamous Cell Carcinoma 16Carcinoma, Ovarian Epithelial 15Unspecified Adult Solid Tumor, Protocol Specific 13Carcinoma, Transitional Cell 13Breast Neoplasms, Male 13Adenocarcinoma of Lung 12Salivary Gland Neoplasms 11Laryngeal Neoplasms 11Small Cell Lung Carcinoma 10Inflammatory Breast Neoplasms 10Uterine Cervical Neoplasms 9

Interventions

Triptorelin Pamoate 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel × Docetaxel × Clear all
NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
75 enrolled
Genitourinary

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Data powered by HemOnc (CC BY 4.0) Colophon âš¡